Edition:
United Kingdom

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

50.17USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$50.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
332,283
52-wk High
$67.10
52-wk Low
$24.15

Chart for

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $3,564.08
Shares Outstanding(Mil.): 64.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

22 Dec 2017

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN)

19 Dec 2017

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN

12 Dec 2017

BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

* Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

21 Nov 2017

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

13 Sep 2017

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

11 Sep 2017

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

15 Aug 2017

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

09 Aug 2017

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

03 Aug 2017

Competitors

Earnings vs. Estimates